key: cord-0278490-qsps93zn authors: Zhang, Yan; Steppe, Paige L.; Kazman, Maxwell W.; Styczynski, Mark P. title: Point-of-care analyte quantification and digital readout via lysate-based cell-free biosensors interfaced with personal glucose monitors date: 2021-09-12 journal: bioRxiv DOI: 10.1101/2021.06.22.449464 sha: 568ecb201f9a856cb3682a13cec6154537f48d46 doc_id: 278490 cord_uid: qsps93zn Field-deployable diagnostics based on cell-free systems have advanced greatly, but on-site quantification of target analytes remains a challenge. Here we demonstrate that Escherichia coli lysate-based cell-free biosensors coupled to a personal glucose monitor (PGM) can enable on-site analyte quantification, with the potential for straightforward reconfigurability to diverse types of analytes. We show that analyte-responsive regulators of transcription and translation can modulate production of the reporter enzyme β-galactosidase, which in turn converts lactose into glucose for PGM quantification. Because glycolysis is active in the lysate and would readily deplete converted glucose, we decoupled enzyme production and glucose conversion to increase endpoint signal output. This lysate metabolism did, however, allow for one-pot removal of glucose present in complex samples (like human serum) without confounding target quantification. Taken together, we show that integrating lysate-based cell-free biosensors with PGMs enables accessible target detection and quantification at the point of need. Table of Contents Graphic have used custom-built, portable electronic devices in place of bulky plate readers for result 48 interpretation and quantification 2, 3, 5 . While these efforts represent promising strides toward 49 quantitative analyte measurement at the sampling site, few of these approaches or devices can 50 match the simplicity, quantification, and digital readout offered by a personal glucose monitor 51 (PGM). Since the product's commercialization in the 1970s, personal glucose monitors have 53 been through decades of refinement and matured into a robust and easily accessible 54 technology that many patients use daily and almost anywhere 6 . As a result, there has been 55 significant research effort to engineer biosensors that can be read by a glucose monitor 7-15 56 rather than trying to engineer entirely new quantification devices that match the PGM's 57 portability and reliability. Recent efforts have even successfully interfaced glucose monitors with 58 cell-free system-based biosensors, though they were subject to significant limitations. The first-59 ever reported use of cell-free systems with a glucose monitor was limited to using reagent 60 complementation strategies 8 , such that it was only used to measure analytes that were required 61 components of the cell-free reaction. A more recent report demonstrated detection of the 62 presence and absence of targets (nucleic acid sequences) but did not aim for analyte 63 quantification 7 . In addition, the demonstration used an expensive, purified protein expression 64 system (PURExpress, at almost $10 per sample) and required a separate, overnight enzymatic 65 conversion step to remove confounding glucose that is present in the sample. The glucose 66 removal step that was used required the user to know in advance the sample glucose levels and 67 then add sample-specific volumes of reagents to clear native glucose from samples without 68 causing unwanted degradation of the glucose generated by the sensing reaction. All of these 69 requirements decrease that approach's potential viability for field-deployable applications. While 70 that report was a significant step forward, the use of a PGM for qualitative, presence/absence 71 diagnosis rather than quantitative measurement meant the strategy did not fully exploit one of 72 the most critical and impactful capabilities offered by PGMs. Even more importantly, for most 73 clinically relevant biomarkers for conditions other than infectious disease, it is the biomarkers' 74 concentration-not merely their presence or absence-that is the criterion for diagnosis 4, 16-18 . For these target analytes, quantification at the point of need is critical and digital readout 76 enables straightforward result interpretation. Here, we aim to expand the repertoire of glucose monitor-mediated analyte detection to 78 include quantification of diverse sets of analytes via lysate-based CFE systems. We first 79 showed that a genetic circuit constitutively expressing the enzyme β-galactosidase (LacZ) in the 80 CFE lysate reaction successfully allows LacZ conversion of lactose to glucose and yields 81 measurable PGM outputs. We then demonstrated analyte-modulated LacZ production and 82 glucose conversion via different biosensing circuits. We successfully used a zinc-responsive 83 transcription factor to generate dose-dependent expression of LacZ to identify zinc deficiency in 84 a human serum matrix at clinically relevant concentrations. We further showed that the same 85 detection strategy could be used to detect and quantify nucleic acid biomarkers from 86 pathogenic E. coli by merely substituting the zinc transcriptional control elements with RNA 87 regulatory elements (toehold switches). In developing these diagnostic sensors, we found that 88 the metabolic pathways active in lysate-based CFE systems 19-23 readily deplete glucose in 89 reactions. As a result, we decoupled LacZ production from glucose conversion and capitalized 90 on this lysate metabolism for one-pot removal of glucose that may be initially present in a 91 complex sample environment (like human serum or other biofluids) without customizing reagent 92 volumes to individual samples, thereby eliminating a separate processing step to remove endogenous glucose required in current PGM-mediated analyte quantification methods 7, 14, 15 . Taken together, our work showcases a broadly applicable and modular strategy for rapid and 95 reliable quantification of target analytes at the point of need, expanding the repertoire of PGM-96 mediated biomarker detection with biosensors expressed in lysate-based CFE systems. Results and Discussion: Lysate-based CFE reaction producing LacZ enzyme can convert lactose to measurable glucose 101 102 The first step toward PGM-mediated analyte quantification using lysate-based CFE 103 reactions was to confirm that the CFE reagents are compatible with commercial PGMs. To 104 verify reagent compatibility and glucose stability, we incubated D-(+)-glucose (hereafter referred 105 to as glucose) at concentrations of 0-25 mM in CFE reactions to span the full PGM detection 106 range and tracked their respective value readouts over time. Compared to glucose standards 107 prepared in water, we observed a slight decrease in signal output for immediate measurement 108 of the same glucose concentration in the CFE matrix ( Figure 1A) . We also found significant 109 glucose consumption in CFE reactions over time ( Figure 1A ). This finding was perhaps 110 unsurprising, as previous reports have observed and characterized significant endogenous 111 glycolytic metabolic activity in CFE lysates 19-23 ; we attributed the loss in signal output over time 112 to enzyme-catalyzed conversion of glucose to glucose-6-phosphate due to residual glycolytic 113 activity in the lysate. Endogenous glycolytic activity in crude E. coli lysate could pose serious problems for 115 CFE-mediated analyte quantification using PGMs, since glucose molecules generated by the 116 reporter enzyme in the CFE reaction would be readily depleted, and thus desired signal would 117 be lost. To address this issue, we chose to decouple reporter enzyme production from enzyme-118 catalyzed glucose production. To assess how fast glucose can be produced for detection by the 119 PGM, we added a plasmid for constitutive expression of the enzyme LacZ to the CFE reaction 120 for 30 to 60 minutes. Following this incubation, a mixture consisting of naproxen and lactose 121 was added to the CFE reaction to terminate transcription in the CFE system (via naproxen), 122 slow down lysate metabolism (via naproxen), and start glucose production via LacZ conversion 123 of lactose to glucose. Different concentrations of plasmid that constitutively express LacZ were 124 used as a testbed model for our eventual goal of LacZ expression that increases based on the 125 amount of analyte present. After 15 minutes of incubation, we observed plasmid dose-126 modulated glucose signal production on the PGM ( Figure 1B) . Naproxen was used here due to 127 its effectiveness at inhibiting CFE reactions without impairing LacZ activity 4 (Figure S1A-D). We 128 anticipate that other small molecule inhibitors added at high concentrations could also be 129 capable of halting the CFE reaction, but we chose naproxen here due to its minimal effects on After successfully verifying plasmid dose-dependent glucose production in CFE systems, we tested whether small molecule inducers could modulate dose-dependent glucose readings 157 on PGMs. We chose zinc as our target analyte for PGM-mediated quantification due to its global 158 health relevance (zinc deficiency is responsible for the deaths of 100,000 children under the age 159 of five worldwide every year) 24, 25 and our group's previous experience in developing a semi- zinc deficiency and toxicity. The common clinical reference range for zinc deficiency is between 214 8.5-11.5 µM (or 2.1-2.9 µM in 25% serum) 4, 24 . Since our assay can accurately measure zinc in 215 this range, our approach can be easily deployed for a quantitative micronutrient monitoring test 216 at home or in resource-limited environments. We further highlight that endogenous glucose present in human serum did not interfere 218 with our PGM readout since the metabolic reactions active in cell-free lysate readily removed 219 serum glucose without impacting protein production (Figure S2A-C) . Previous efforts using 220 PGMs for sensing in serum matrices have required additional steps to remove the confounder of 221 serum glucose from reporter measurements 14, 15 , since serum glucose would be expected to 222 vary from patient to patient-the very reason the PGM exists-and thus interfere with 223 quantitative interpretation of the biosensor readout. Some of the previously reported approaches 224 to solving this problem would be infeasible for practical field application. With our approach, the 225 glucose consumption that was initially a potential obstacle in the use of lysate-based CFE has 226 been repurposed as a distinct advantage that allows quantification across highly variable patient 227 sample matrices. Furthermore, our strategy of using a transcription factor-based, small molecule inducible 229 genetic circuit is modular and easily generalizable to detect other small molecule targets. To Although our current nucleic acid sensors could not detect targets at physiologically 301 relevant concentrations (typically attomolar to femtomolar levels), an upstream amplification 302 step can be implemented to bring initial nucleic acid concentrations up to the detection limit 3, 7, 303 29 . Previous work has shown robust concentration-dependent toehold switch activation with 304 femto-to pico-molar of triggers amplified via isothermal amplification techniques 29 . Further, we 305 note that although for detection of infectious diseases (such as COVID-19, Zika, and Ebola 306 virus), a binary yes/no result may often be sufficient for diagnosis 2, 3, 30 , there are many cases 307 where continuous monitoring and quantification of viral load is essential for assessing treatment 308 efficacy and determining disease prognosis 31 . Having a low-cost, portable, and reliable 309 quantification device can empower patients and healthcare workers to make faster and better 310 medical decisions at the point of need. Conclusion: Our work demonstrates that CFE lysate-based biosensors can be easily coupled to a 315 PGM for rapid and reliable analyte quantification at the point of need. The resulting platform is It is worth noting that for successful field deployment of these PGM-based sensors, 349 additional investigation will be necessary. One area that such investigations should focus on is 350 the reduction of batch-to-batch variability in crude lysate and reagent preparation. Interlaboratory variability in cell-free lysate, reagent, and reaction preparation is known to 352 potentially have an impact on quantitative outputs of cell-free reactions 34 . When we assessed 353 the PGM's ability to accurately quantify targets using cell-free reactions from five crude lysate 354 batches, the inter-lysate variability was found to be low, though the variability due to batches of 355 cell-free reagents was a bit higher ( Figure S3 ). This suggests the importance of standardization, 356 quality assurance, and quality control if this process were to be scaled up for manufacturing and 357 distributed use. Another area worth further investigation is the sensitivity of assay results to 358 perturbations in the time and temperature during the LacZ production and glucose conversion 359 steps. If sensitivity to such perturbations is high, one potential mitigating strategy would be to 360 use a set of standards that could be run in parallel with the test reaction for additional 361 validation 4 ; we note that some PGMs already require some degree of calibration by the user. Another possibility could be to engineer a companion device to automate reagent dispensing Cell-Free Reactions The cell-free reaction composition was as previously described by Kwon and Jewett 37 . All lysate and reagent master mixes were thawed on ice and had less than 3 freeze-thaw 390 cycles. All reactions were assembled on ice and in PCR tube strips. The reaction master mix 391 containing lysate was vortexed at a medium-high setting to ensure homogenous mixing before For reactions read on a PGM, each assembled cell-free reaction was 9 µL in volume and 408 placed in a PCR tube with the cap on to prevent evaporation. Reactions were incubated at 409 37 °C in a thermocycler for the specified amount of time before glucose measurement. For 410 reactions quenched with the naproxen-lactose mix, 1 µL of the 10x quench mix (100 mM 411 naproxen sodium and 400 mM lactose) was added to each reaction and the mixture was 412 vortexed at medium-high setting, settled to the bottom of the tube using a mini centrifuge, and incubated at 37 ˚C for 15 minutes before measurement on a PGM. The same concentration of 414 the naproxen-lactose mix was added to all cell-free reactions. A glucose oxidase-based PGM (OneTouch Ultra 2 Blood Glucose Monitoring System, LifeScan Inc) and accompanying test strips (OneTouch Ultra Test Strips, LifeScan Inc) were 419 used for glucose measurement. Once the glucose-generating step of the reaction was 420 completed, 2 µL of each reaction was spotted on the test strip and measured with the PGM. Because the PGM's readout range is from 20 to 600 mg/dL, values below or above the meter 422 threshold were assigned a value of 20 mg/dL or 600 mg/dL, respectively. 423 424 Cell-free gene expression: an expanded 455 repertoire of applications Paper-based synthetic gene networks Rapid, Low-Cost Detection of Zika Virus Using Programmable 461 Biomolecular Components Point-of-care biomarker quantification enabled by sample-specific calibration Cell-free biosensors for rapid detection of water contaminants A history of blood glucose meters and their role in self-470 monitoring of diabetes mellitus A glucose meter interface for point-of-care gene circuit-475 based diagnostics Cell-Free Protein Synthesis for Rapid Analysis of Amino Acids The application of personal glucose meters as 480 universal point-of-care diagnostic tools Using the widely available blood glucose meter to monitor 482 insulin and HbA1c Using personal glucose meters and functional DNA sensors to quantify a 484 variety of analytical targets Portable and quantitative detection of protein biomarkers and small 486 molecular toxins using antibodies and ubiquitous personal glucose meters Using commercially available personal glucose meters for portable 489 quantification of DNA Target-responsive "sweet" hydrogel with glucometer readout for portable and 492 quantitative detection of non-glucose targets Dose-Dependent Response of Personal 494 Glucose Meters to Nicotinamide Coenzymes: Applications to Point-of-Care Diagnostics of Many 495 Non-Glucose Targets in a Single Step Biomarkers in nutrition: new frontiers in research and application Biomarkers of cardiovascular disease: molecular basis and practical 502 considerations Energizing cell-free protein synthesis with glucose 504 metabolism A cost-effective polyphosphate-based metabolism fuels an all 506 E. coli cell-free expression system Enhancing control of cell-free metabolism 508 through pH modulation Metabolic Profiling of Escherichia 510 coli-based Cell-Free Expression Systems for Process Optimization Metabolic Dynamics in 513 Escherichia coli-based Cell-Free Systems Biomarkers of Nutrition for Development (BOND)-Zinc Review Evidence-based interventions for improvement of maternal and child nutrition: what 520 can be done and at what cost? Lancet Infection by Shiga toxin-producing Escherichia coli: an overview. Mol 522 Biotechnol Protocell Arrays for Simultaneous Detection of Diverse Analytes Toehold switches: de-novo-designed 527 regulators of gene expression A low-cost paper-based synthetic biology platform for 530 analyzing gut microbiota and host biomarkers Assay Techniques and Test 533 Development for COVID-19 Diagnosis Quantification of viral load: clinical 535 relevance for human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. 536 Intervirology 538 Design of a Transcriptional Biosensor for the Portable, On-Demand Detection of Cyanuric Acid Point-of-Use Detection of Environmental Fluoride via a Cell-Free Riboswitch-Based 542 Quantification of Interlaboratory Cell-Free Protein Synthesis Variability Creating CRISPR-responsive smart materials for diagnostics 549 and programmable cargo release Programmable CRISPR-responsive smart materials High-throughput preparation methods of crude extract for 554 robust cell-free protein synthesis Free Extract Preparation for in Vitro Activation of Transcriptional Genetic Circuitry Conflict of Interest: The authors declare no conflict of interest.